Door Pharma is a discovery phase biotech company that focuses on virus structural proteins as antiviral targets. The hypothesis underlying our work is that formation of an infectious virus requires the right interplay between viral components. Virus structural proteins have architectural roles in the virus particle and are also typically actors in many stages of a viral life cycle. A disruption in the evolved functions of virus structural proteins can lead to a defective virus.

Small molecules that bind to target proteins can disrupt assembly and other functions. Furthermore, targeting viral proteins can facilitate specificity while minimizing off-target activities.

Door Pharmaceuticals was founded in 2018 by HBV researcher, Adam Zlotnick, PhD, a professor of Molecular and Cellular Biochemistry at Indiana University. Professor Zlotnick is also a fellow of the American Academy of Microbiology and of the AAAS.